MED27

Across TCGA pan-cancer cohorts, MED27 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MED27 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED27 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED27 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where MED27 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	1.000	0.660	.004	29	view →
LUAD	DFS	Tertile	II,III,IV	0.952	0.631	.007	8	view →
CCRCC	DFS	Tertile	IV	0.961	0.196	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MED27–LSCC (OS)

Open the LSCC breakdown →